| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
|
Purity: ≥98%
| Targets |
HSV-1
|
|---|---|
| ln Vitro |
In MCF-7 cells, 2-Deoxy-D-glucose (2-DG), 4, 8, or 16 mM, dramatically decreased ATP levels in a dose- and time-dependent manner that was comparable to the effect of 2-DG on cell growth. exposure to 4, 8 or 16 mM 2-Deoxy-D-glucose 1, 3 or for 5 days in a way that depends on the dose and the amount of time [1]. When 2-DG is administered, pentose phosphate pathway (PPP) responders are upregulated, and 6-phosphate endpoint dehydrogenase produces more NADPH. The 2-DG reduced form of glutathione is elevated in NB4 cells due to an increase in NADPH and an upregulation of glutathione synthetase expression [3].
|
| ln Vivo |
2-Deoxy-D-glucose (0.03%, w/w) postponed the possible beginning of breast cancer and led to a statistically significant 7% reduction in final body weight [1]. 2. During extraction, 2-Deoxy-D-glucose (3 mmol/kg, iv) is lowered in a dose-dependent manner [2].
Note: Despite the numerous preclinical and clinical studies, the use of 2-DG in cancer and viral treatment has been limited. Its rapid metabolism and short half-life (according to Hansen et al., after treatment with infusion of 50 mg/kg2-DG, its plasma half-life was only 48 min), make 2-DG a relatively poor drug candidate. Moreover, 2-DG must be given at relatively high concentrations (≥5 mmol/L) to compete with blood glucose. According to Stein et al., the dose of 45 mg/kg received orally on days 1–14 was defined as safe because patients did not experience any dose-limiting toxicities. Notably, at the dose of 60 mg/kg, two patients experienced dose-limiting toxicity of grade 3–asymptomatic QTc prolongation. According to former studies published by Burckhardt et al. and Stalder et al., among patients exposed to 2-DG, non-specific T wave flattening and QT prolongation, without any event of severe arrhythmia, developed.[4] |
| Enzyme Assay |
ATP assay. The effect of 2-DG on ATP level in the cells was determined using an ENLITEN ATP assay kit (Promega Corporation, Kadison, WI), the bioluminescence was detected using a TD 20/20 luminometer (Turner Biosystem, Sunnyvale, CA), and the amount of ATP per well was standardized by the cell number estimated by crystal violet method described above.[1]
|
| Cell Assay |
Using MCF-7 human breast cancer cells to investigate the signaling pathways perturbed by disruption of glucose metabolism, 2-DG reduced cell growth and intracellular ATP in a dose- and time-dependent manner (P < 0.01). Treatment with 2-DG increased levels of phosphorylated AMP-activated protein kinase and Sirt-1 and reduced phosphorylated Akt (P < 0.05). These studies support the hypothesis that DER inhibits carcinogenesis, in part, by limiting glucose availability and that energy metabolism is a target for the development of ERMA for chemoprevention.[1]
|
| Animal Protocol |
For the carcinogenesis study, ninety 21-day-old female Sprague-Dawley rats were injected i.p. with 50 mg of 1-methyl-1-nitrosourea per kilogram of body weight. Following injection, animals were ad libitum fed AIN-93G diet containing 0.00%, 0.02%, or 0.03% (w/w) 2-DG for 5 weeks. 2-DG decreased the incidence and multiplicity of mammary carcinomas and prolonged cancer latency (P < 0.05). The 0.02% dose of 2-DG had no effect on circulating levels of glucose, insulin, insulin-like growth factor-I, IGF binding protein-3, leptin, or body weight gain. [1]
|
| References |
[1]. Zhu Z, et al. 2-Deoxyglucose as an energy restriction mimetic agent: effects on mammary carcinogenesis and on mammary tumor cell growth in vitro. Cancer Res. 2005 Aug 1;65(15):7023-30.
[2]. Ueyama A, et al. Nonradioisotope assay of glucose uptake activity in rat skeletal muscle using enzymatic measurement of 2-deoxyglucose 6-phosphate in vitro and in vivo. Biol Signals Recept. 2000 Sep-Oct;9(5):267-74. [3]. Miwa H, et al. Leukemia cells demonstrate a different metabolic perturbation provoked by 2-deoxyglucose. Oncol Rep. 2013 May;29(5):2053-7 [4]. Int J Mol Sci. 2020 Jan; 21(1): 234. |
| Molecular Formula |
C6H12O5
|
|---|---|
| Molecular Weight |
164.1565
|
| Exact Mass |
164.07
|
| Elemental Analysis |
C, 43.90; H, 7.37; O, 48.73
|
| CAS # |
154-17-6
|
| Related CAS # |
2-Deoxy-D-glucose-d;188004-07-1;2-Deoxy-D-glucose-13C;201612-55-7;2-Deoxy-D-glucose-13C-1;119897-50-6
|
| Appearance |
White to off-white solid powder
|
| Source |
Endogenous metabolite
|
| LogP |
-2.9
|
| tPSA |
98Ų
|
| SMILES |
O([H])[C@]([H])([C@@]([H])(C([H])([H])O[H])O[H])[C@@]([H])(C([H])([H])C([H])=O)O[H]
|
| InChi Key |
VRYALKFFQXWPIH-PBXRRBTRSA-N
|
| InChi Code |
InChI=1S/C6H12O5/c7-2-1-4(9)6(11)5(10)3-8/h2,4-6,8-11H,1,3H2/t4-,5-,6+/m1/s1
|
| Chemical Name |
2-Deoxy-D-arabinohexose
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 24 mg/mL (~146.20 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 130 mg/mL (791.91 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
Solubility in Formulation 2: ~130 mg/mL (~792 mM) in PBS (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.0916 mL | 30.4581 mL | 60.9162 mL | |
| 5 mM | 1.2183 mL | 6.0916 mL | 12.1832 mL | |
| 10 mM | 0.6092 mL | 3.0458 mL | 6.0916 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA